294 filings
Page 3 of 15
6-K
rg4c0djp8bi9iorg
8 May 23
Report of Foreign Private Issuer
6:19am
6-K
7iqncddghsywaopcp
2 May 23
Report of Foreign Private Issuer
6:04am
6-K
usg4yta
19 Apr 23
Q3 FY23 Business Update Presentation
6:06am
6-K
2kif4nl 4qyf1nqloapz
6 Apr 23
Report of Foreign Private Issuer
6:02am
6-K
1r9a2cg1iy
28 Feb 23
Report of Foreign Private Issuer
3:04pm
6-K
98qu23vx
28 Feb 23
Report of Foreign Private Issuer
6:02am
6-K
eou194sgqr7a4m4ea
15 Feb 23
Report of Foreign Private Issuer
2:23pm
6-K
ebqlkitdhfk8cg4r w2
24 Jan 23
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
9:09pm
6-K
lkhv eter
18 Jan 23
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
6:06am
6-K
4piuedpfa
17 Jan 23
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
6:06am
6-K
98l9r5smd4t413fh62
22 Dec 22
Immuron Receives FDA Approval for Travelan IND Application
7:31pm
6-K
xti m2g5j8fk28
5 Dec 22
Immuron Submits IND Application To FDA for Travelan
6:03am
6-K
lx18ewe0
1 Dec 22
Report of Foreign Private Issuer
4:52pm
6-K
97uy7vnc8q0
21 Nov 22
Report of Foreign Private Issuer
6:15am
6-K
ydiro62zl
21 Nov 22
Report of Foreign Private Issuer
6:02am
6-K
rg4qxgu5zpe8ws 0t
16 Nov 22
Immuron completes strategic investment in leading gut health biotech Ateria Health
6:07am
6-K
u1eh78 8fh
26 Oct 22
Report of Foreign Private Issuer
6:10am
6-K
9j59srxex8q ggcy
21 Oct 22
Notice of 2022 Annual General Meeting and Explanatory Memorandum
6:12am
6-K
t71wml
13 Oct 22
Immuron strategic investment in leading gut health biotech Ateria Health
6:10am
6-K
r0c826 cq7
4 Oct 22
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
6:01am